Zobrazeno 1 - 10
of 183
pro vyhledávání: '"John O'Quigley"'
Autor:
John O'Quigley
Publikováno v:
Journal of Clinical Oncology. 40:3537-3545
A statistical test for the presence of treatment effects on survival will be based on a null hypothesis (absence of effects) and an alternative (presence of effects). The null is very simply expressed. The most common alternative, also simply express
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1fd8afc3917b8bdcc3dcfb34f27300f
https://doi.org/10.1200/jco.21.01811
https://doi.org/10.1200/jco.21.01811
A hypothetical example of an updated DTP for Cohorts 4 to 6 in the Viola trial after observing 0/3 DLT at Dose 0, 1/3 DLT at Dose 1 and 0/3 DLT at Dose 1 for Cohorts 1 to 3 respectively (i.e. pathway 5 in Table 2). This table presents all 64 pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d6a311f1fba250c7dbe3ed61b3a83b0
https://doi.org/10.1158/1078-0432.22461983.v1
https://doi.org/10.1158/1078-0432.22461983.v1
Original DTP for Cohorts 1 to 3 (with cohort size of 3) with all 64 pathways without stopping early for excessive toxicity in Viola. The design will always recommend staying at the lowest dose even when high numbers of DLTs are observed at the lowest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::156394ff520ecab5235b2eb74bcd6cc7
https://doi.org/10.1158/1078-0432.22461986
https://doi.org/10.1158/1078-0432.22461986
Autor:
John O'Quigley, Sarah Zohar, David M. Hyman, John F. Gerecitano, David R. Spriggs, Mrinal Gounder, Alexia Iasonos
The rate of observed dose-limiting toxicities (DLT) determines the maximum tolerated dose (MTD) in phase I trials. There are cases in which non–drug-related toxicities or other-cause toxicities (OCT) are flagged as DLTs, or vice versa, due to attri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24ee84941e56ad45f0facd6d85c8bc37
https://doi.org/10.1158/1078-0432.c.6523119.v1
https://doi.org/10.1158/1078-0432.c.6523119.v1
The ever-increasing pace of development of novel therapies mandates efficient methodologies for assessment of their tolerability and activity. Evidence increasingly support the merits of model-based dose-finding designs in identifying the recommended
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2208128856dc3c1e06195cb93755bf
https://doi.org/10.1158/1078-0432.c.6524975.v1
https://doi.org/10.1158/1078-0432.c.6524975.v1
DTP-Heatmap of risk of lowest dose being too toxic. This figure presents a heatmap to highlight any case where there is a high chance that the lowest dose is too toxic (greater than 0.3 DLT rate) based on the accumulated data in each pathway for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bed88b1a40b7d53949a3e36532cc351
https://doi.org/10.1158/1078-0432.22461989
https://doi.org/10.1158/1078-0432.22461989
Autor:
John O'Quigley, Sarah Zohar, David M. Hyman, John F. Gerecitano, David R. Spriggs, Mrinal Gounder, Alexia Iasonos
PDF file, 50K, Supp. Table 1. Dose-escalation algorithm for 3+3 method.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a599ed6e8923f404eb4c1a57c4872d
https://doi.org/10.1158/1078-0432.22455807.v1
https://doi.org/10.1158/1078-0432.22455807.v1
A hypothetical example of an updated DTP for Cohorts 7 to 9 in the Viola trial with the final recommended MTD. This is based on observing DLT outcomes of 0/3 DLT at Dose 0, 1/3 DLT at Dose 1 and 0/3 DLT at Dose 1 for Cohorts 1 to 3 respectively (path
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598d255369c85839fe17d38eb0557e40
https://doi.org/10.1158/1078-0432.22461980.v1
https://doi.org/10.1158/1078-0432.22461980.v1
Publikováno v:
Stat Methods Med Res
Many clinical trials incorporate stopping rules to terminate early if the clinical question under study can be answered with a high degree of confidence. While common in later-stage trials, these rules are rarely implemented in dose escalation studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::335e60745ba156b3ad7fdbd39d13da00
https://doi.org/10.1177/09622802211064996
https://doi.org/10.1177/09622802211064996
Autor:
Sean M. Devlin, John O'Quigley
Publikováno v:
Contemporary clinical trials. 125
In studies of survival and its association with treatment and other prognostic variables, elapsed time alone will often show itself to be among the strongest, if not the strongest, of the predictor variables. Kaplan-Meier curves will show the overall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5da8730eef0961b73db9559b051dafb7
https://pubmed.ncbi.nlm.nih.gov/36473681
https://pubmed.ncbi.nlm.nih.gov/36473681